Bavarian Nordic vaccine helps prolong life in prostate cancer trial

February 24, 2015 7:42 PM

15 0

(Reuters) - An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute.

Shares of Bavarian Nordic closed up almost 12 percent in Copenhagen after the company released the data on Tuesday.

Read more

To category page